Sectioning remote imagery for characterization of Avena sterilis infestations. Part A: Weed abundance

Software was developed to spatially assess key crop characteristics from remotely sensed imagery. Sectioning and Assessment of Remote Images (SARI ®), written in IDL ® works as an add-on to ENVI ®, has been developed to implement precision agriculture strategies. SARI ® splits field plot images into grids of rectangular >micro-images> or >micro-plots>. The micro-plot length and width were defined as multiples of the image spatial resolution. SARI ® calculates different indicators for each micro-plot, including the integrated pixel digital values. Studies on weed patches were done with SARI ® using ground-truth data and remote images of two wheat plots infested with Avena sterilis at LaFloridaII and Navajas (Southern Spain). Patches of A. sterilis represented 47.5 and 19.2% of the field areas at the two locations, respectively; the infested areas were a combination of a few large and several small patches. At LaFloridaII, 2.1% of all patches were >500 m 2 and 55.0% of all patches were smaller than 10 m 2. Based on ground-truth weed abundance data, SARI ® output includes geo-referenced and visual herbicide prescription maps, which could be used with variable-rate application equipment. © 2011 Springer Science+Business Media, LLC.This research was partially financed by the Spanish Commission of Science and Technology through the projects AGL2007-60926 and AGL2010-15506.This research was partially financed by the Spanish Commission of Science and Technology through the projects AGL2007-60926 and AGL2010-15506.Peer Reviewe

Mapeo y cuantificación de las infestaciones de Orobanche crenata en guisantes mediante teledetección

Póster presentado en el XIII Congreso Nacional de Malherbología celebrado en La Laguna (Tenerife) en noviembre de 2011.Los jopos (Orobanche crenata Forsk.) son especies parásitas de cultivos leguminosos, muy extendidas en el área mediterránea (García-Torres et al., 1994). La agricultura de precisión trata de determinar y manejar la distribución espacial de factores bióticos, tales como malas hierbas y patógenos, y de factores abióticos y así fundamentar la aplicación de inputs a dosis variables, ajustados a las necesidades de pequeñas aéreas o sub-parcelas. El objetivo de este trabajo es describir brevemente la discriminación de rodales de jopos en el cultivo de guisante (Pisum sativum L.) mediante imágenes remotas multiespectrales y su manejo de precisión mediante el software SARI® (Sectioning and Assessment of Remote Images) un módulo complementario de ENVI® que divide y cuantifica la imagen de una parcela en sub-parcelas.Esta investigación se ha financiado en parte a través de los proyectos AGL2007-60926 (FEDER) y AGL2010-15506 (FEDER).Peer reviewe

Myeloid-derived suppressor cells are increased in lung transplant recipients and regulated by immunosuppressive therapy

Lung transplantation remains as a primary treatment for end-stage lung diseases. Although remarkable improvement has been achieved due to the immunosuppressive protocols, long-term survival for lung transplant recipients (LTR) is still limited. In the last few decades, an increasing interest has grown in the study of dysregulation of immune mechanisms underlying allograft failure. In this regard, myeloid-derived suppressor cells (MDSCs) could play an important role in the promotion of graft tolerance due to their immune regulatory function. Here, we describe for the first time circulating subsets MDSCs from LTR at several time points and we evaluate the relationship of MDSCs with sort-term lung transplant outcomes. Although no effect of MDSCs subsets on short-term clinical events was observed, our results determine that Mo-MDSCs frequencies are increased after acute cellular rejection (ACR), suggesting a possible role for Mo-MDSCs in the development of chronic lung allograft dysfunction (CLAD). Therefore, whether MDSCs subsets play a role as biomarkers of chronic rejection remains unknown and requires further investigations. Also, the effects of the different immunosuppressive treatments on these subpopulations remain under research and further studies are needed to establish to what extend MDSCs immune modulation could be responsible for allograft acceptance.FUNDING: This work was supported by grants from the FIS-ISCII (PI16/ 01585) to ML-H and NVAL16/22 to DS. ACKNOWLEDGMENTS We are grateful to María José Ortı́z González (IDIVAL, Santander, Spain) for her excellent technical support. ACKNOWLEDGMENTS: We are grateful to María José Ortı́z González (IDIVAL, Santander, Spain) for her excellent technical support

Ensayo, ¿Qué significa tener derechos?

A lo largo de la historia, la concepción de “lo que realmente significa tener derechos” ha sido cuestión de un debate muy controversial del pensamiento y practica humana en áreas de diversa índole, un debate profundo el cual sirve como punto de partida para un desarrollo social sano y, por ende, para el bienestar común-individual de los integrantes de un estado u sociedad, desde el gobernante hasta el gobernado y en viceversa, tomaremos el derecho fundamental que prima sobre cualquier otro (el derecho a la vida) como argumento principal de lo que, en nuestra opinión, realmente que significa tener derechos, teniendo en cuenta sus antecedentes junto con sus concepciones tanto iusnaturalistas como positivistas y como éstas se relacionan entre sí de manera casi simbiótica para brindar seguridad a los bienes jurídicos fundamentales de cada persona y dar una idea de lo que podría ser una de las respuestas a esta cuestión histórica, basándonos en diversas opiniones fidedignas, pensamientos filosóficos que nos darán idea acerca de algunas concepciones de la naturaleza humana y la estructuración de nuestra propia constitución, primando el derecho a la vida sobre cualquier otro tema plasmado en ella, respondiendo a dos cuestionamientos ¿Tener derechos es hacer valorar nuestra identidad? Con un solo fin ¿Qué significa tener derechos

Comportamiento epidemiológico de la obesidad y factores de riesgo asociados en la población rural de Cumbe, Ecuador

Introducción: La obesidad constituye actualmente una de las más importantes pandemias a nivel mundial con importantes consecuencias personales, familiares y gubernamentales. Los datos epidemiológicos de la obesidad en poblaciones rurales de Ecuador son limitados, por lo que el objetivo de esta investigación fue evaluar la prevalencia y los factores asociados a la obesidad en individuos adultos de la parroquia rural de Cumbe, Ecuador. Materiales y métodos: Se realizó un estudio de campo, analítico, transversal con muestreo aleatorio multietápico, que incluyó a 374 individuos de ambos sexos mayores a 18 años residenciados en la parroquia rural de Cumbe, a quienes se les aplicó historia clínica completa. La obesidad se definió según los criterios de la Organización Mundial de la Salud (OMS) en normopeso, sobrepeso y obesidad. Se construyó un modelo de regresión logística multivariante para la estimación de Odds Ratios (IC95%) para factores asociados a la obesidad. Resultados: La prevalencia de sobrepeso y obesidad fue del 34,7% (n=140) y 19% (n=71). Las mujeres presentaron una mayor prevalencia de obesidad (21,8%), que los hombres (13,5%). Los factores asociados a obesidad fueron: el sexo femenino (OR=3,61; IC95%:1,38-9,47; p=0,009), el antecedente personal de diabetes mellitus tipo 2 (OR=3,54; IC95%:1,10-11,39; p=0,034), ser exfumador (OR=3,48; IC95%:1,02-11,83; p=0,045), realizar actividad física baja (OR=2,17; IC95%:1,02-4,63; p=0,043), la circunferencia abdominal elevada (OR=3,23; IC95%:1,37-7,62, p=0,007) y el antecedente de hipertensión (OR=5,44, IC95%:2,04- 14,45; p=0,001). Conclusiones: Se evidenció una baja prevalencia de obesidad similar a las reportadas en el país, pero bajas en comparación de otras latitudes. Ser mujer, exfumador, realizar actividad física baja, hipertenso, diabético o con obesidad abdominal fueron los factores asociados a obesidad, por lo que deben tomarse en cuenta al momento de realizar la prevención y promoción de la salud

The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil

A growing interest has emerged in the beneficial effects of plant-based diets for the prevention of cardiovascular disease, diabetes and obesity. The Mediterranean diet, one of the most widely evaluated dietary patterns in scientific literature, includes in its nutrients two fluid foods: olive oil, as the main source of fats, and a low-to-moderate consumption of wine, mainly red, particularly during meals. Current mechanisms underlying the beneficial effects of the Mediterranean diet include a reduction in inflammatory and oxidative stress markers, improvement in lipid profile, insulin sensitivity and endothelial function, as well as antithrombotic properties. Most of these effects are attributable to bioactive ingredients including polyphenols, mono- and poly-unsaturated fatty acids. Polyphenols are a heterogeneous group of phytochemicals containing phenol rings. The principal classes of red wine polyphenols include flavonols (quercetin and myricetin), flavanols (catechin and epicatechin), anthocyanin and stilbenes (resveratrol). Olive oil has at least 30 phenolic compounds. Among them, the main are simple phenols (tyrosol and hydroxytyrosol), secoroids and lignans. The present narrative review focuses on phenols, part of red wine and virgin olive oil, discussing the evidence of their effects on lipids, blood pressure, atheromatous plaque and glucose metabolism

Ethnicity and Clinical Outcomes in Patients Hospitalized for COVID-19 in Spain: Results from the Multicenter SEMI-COVID-19 Registry

Background: This work aims to analyze clinical outcomes according to ethnic groups in patients hospitalized for COVID-19 in Spain. (2) Methods: This nationwide, retrospective, multicenter, observational study analyzed hospitalized patients with confirmed COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry) from 1 March 2020 to 31 December 2021. Clinical outcomes were assessed according to ethnicity (Latin Americans, Sub-Saharan Africans, Asians, North Africans, Europeans). The outcomes were in-hospital mortality (IHM), intensive care unit (ICU) admission, and the use of invasive mechanical ventilation (IMV). Associations between ethnic groups and clinical outcomes adjusted for patient characteristics and baseline Charlson Comorbidity Index values and wave were evaluated using logistic regression. (3) Results: Of 23,953 patients (median age 69.5 years, 42.9% women), 7.0% were Latin American, 1.2% were North African, 0.5% were Asian, 0.5% were Sub-Saharan African, and 89.7% were European. Ethnic minority patients were significantly younger than European patients (median (IQR) age 49.1 (40.5-58.9) to 57.1 (44.1-67.1) vs. 71.5 (59.5-81.4) years, p < 0.001). The unadjusted IHM was higher in European (21.6%) versus North African (11.4%), Asian (10.9%), Latin American (7.1%), and Sub-Saharan African (3.2%) patients. After further adjustment, the IHM was lower in Sub-Saharan African (OR 0.28 (0.10-0.79), p = 0.017) versus European patients, while ICU admission rates were higher in Latin American and North African versus European patients (OR (95%CI) 1.37 (1.17-1.60), p < 0.001) and (OR (95%CI) 1.74 (1.26-2.41), p < 0.001). Moreover, Latin American patients were 39% more likely than European patients to use IMV (OR (95%CI) 1.43 (1.21-1.71), p < 0.001). (4) Conclusion: The adjusted IHM was similar in all groups except for Sub-Saharan Africans, who had lower IHM. Latin American patients were admitted to the ICU and required IMV more often

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine’s registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

Background: Limited evidence exists on the role of glucose-lowering drugs in patients with COVID-19. Our main objective was to examine the association between in-hospital death and each routine at-home glucose-lowering drug both individually and in combination with metformin in patients with type 2 diabetes mellitus admitted for COVID-19. We also evaluated their association with the composite outcome of the need for ICU admission, invasive and non-invasive mechanical ventilation, or in-hospital death as well as on the development of in-hospital complications and a long-time hospital stay. Methods: We selected all patients with type 2 diabetes mellitus in the Spanish Society of Internal Medicine's registry of COVID-19 patients (SEMI-COVID-19 Registry). It is an ongoing, observational, multicenter, nationwide cohort of patients admitted for COVID-19 in Spain from March 1, 2020. Each glucose-lowering drug user was matched with a user of other glucose-lowering drugs in a 1:1 manner by propensity scores. In order to assess the adequacy of propensity score matching, we used the standardized mean difference found in patient characteristics after matching. There was considered to be a significant imbalance in the group if a standardized mean difference > 10% was found. To evaluate the association between treatment and study outcomes, both conditional logit and mixed effect logistic regressions were used when the sample size was ≥ 100. Results: A total of 2666 patients were found in the SEMI-COVID-19 Registry, 1297 on glucose-lowering drugs in monotherapy and 465 in combination with metformin. After propensity matching, 249 patients on metformin, 105 on dipeptidyl peptidase-4 inhibitors, 129 on insulin, 127 on metformin/dipeptidyl peptidase-4 inhibitors, 34 on metformin/sodium-glucose cotransporter 2 inhibitor, and 67 on metformin/insulin were selected. No at-home glucose-lowering drugs showed a significant association with in-hospital death; the composite outcome of the need of intensive care unit admission, mechanical ventilation, or in-hospital death; in-hospital complications; or long-time hospital stays. Conclusions: In patients with type 2 diabetes mellitus admitted for COVID-19, at-home glucose-lowering drugs showed no significant association with mortality and adverse outcomes. Given the close relationship between diabetes and COVID-19 and the limited evidence on the role of glucose-lowering drugs, prospective studies are needed

Respiratory Polygraphy Patterns and Risk of Recurrent Cardiovascular Events in Patients With Acute Coronary Syndrome

Introduction: Obstructive sleep apnea (OSA) severity is based on the apnea-hypopnea index (AHI). The AHI is a simplistic measure that is inadequate for capturing disease severity and its consequences in cardiovascular diseases (CVDs). Deleterious effects of OSA have been suggested to influence the prognosis of specific endotypes of patients with acute coronary syndrome (ACS). We aim to identify respiratory polygraphy (RP) patterns that contribute to identifying the risk of recurrent cardiovascular events in patients with ACS. Methods: Post hoc analysis of the ISAACC study, including 723 patients admitted for a first ACS (NCT01335087) in which RP was performed. To identify specific RP patterns, a principal component analysis (PCA) was performed using six RP parameters: AHI, oxygen desaturation index, mean and minimum oxygen saturation (SaO2), average duration of events and percentage of time with SaO2 < 90%. An independent HypnoLaus population-based cohort was used to validate the RP components. Results: From the ISAACC study, PCA showed that two RP components accounted for 70% of the variance in the RP data. These components were validated in the HypnoLaus cohort, with two similar RP components that explained 71.3% of the variance in the RP data. The first component (component 1) was mainly characterized by low mean SaO2 and obstructive respiratory events with severe desaturation, and the second component (component 2) was characterized by high mean SaO2 and long-duration obstructive respiratory events without severe desaturation. In the ISAACC cohort, component 2 was associated with an increased risk of recurrent cardiovascular events in the third tertile with an adjusted hazard ratio (95% CI) of 2.44 (1.07 to 5.56; p-value = 0.03) compared to first tertile. For component 1, no significant association was found for the risk of recurrent cardiovascular events. Conclusion: A RP component, mainly characterized by intermittent hypoxemia, is associated with a high risk of recurrent cardiovascular events in patients without previous CVD who have suffered a first ACS.Instituto de Salud Carlos III (ISCIII; PI10/02763, PI10/02745, PI18/00449, and PI19/00907), co-funded by FEDER, “Una manera de hacer europa,” IRBLleida – Fundació Pifarré, CERCA Programme/Generalitat de Catalunya, SEPAR, ResMed Ltd. (Australia), Esteve-Teijin (Spain), Oxigen Salud (Spain), Associació Lleidatana de Respiratori (ALLER), and Sociedad Española de Sueño (SES). AZ is the recipient of a predoctoral fellowship “Ajuts 2021 de Promoció de la Recerca en Salut-9a edició” from IRBLleida/Diputació de Lleida. JD acknowledges receiving financial support from ISCIII (Miguel Servet 2019: CP19/00108), co-funded by the European Social Fund (ESF), “Investing in your future.” MS-d-l-T has received financial support from a “Ramón y Cajal” grant (RYC2019-027831-I) from the “Ministerio de Ciencia e Innovación – Agencia Estatal de Investigación” co-funded by the European Social Fund (ESF)/“Investing in your future.” FB received funding from from ResMed (an Australian company that develops products related to sleep apnea), the Health Research Fund, the Spanish Ministry of Health, the Spanish Respiratory Society, the Catalonian Cardiology Society, Esteve-Teijin (Spain), Oxigen Salud (Spain), and ALLER. The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication